University of Tokyo Edge Capital has returned to invest in AI-assisted cardiac diagnosis technology developer Tricog Health.
India-based heart disease diagnostics business Tricog Health has obtained $10.5m in a series B round featuring University of Tokyo Edge Capital (Utec), the institution’s venture capital unit, the Economic Times reported today.
Aflac Ventures, a subdivision of supplemental insurance provider Aflac’s collaborative innovation arm, Aflac Innovation Partners, also participated, as did venture firm Inventus Capital.
The round was also backed by VC fund Blume Ventures, impact investment vehicle TeamFund and startup builder and consultancy Dream Incubator.
Founded in 2014, Tricog has built a technology platform that applies artificial intelligence to assist in the diagnosis of cardiac disease.
Tricog’s Insta ECG system combines electrocardiogram monitoring with cloud-based analytics, and is already deployed in more than 2,500 hospitals, clinics and diagnostics labs.
Tricog will invest funding in its product and growth strategy, building out across Asian and African countries including China, Malaysia and Singapore as well as in Japan, where Tricog and Utec have been collaborating.
Utec joined unnamed investors to inject $4m into Tricog in early 2018, following a series A round of undisclosed size in 2016 backed by Inventus Capital Partners, Blume Ventures and multiple angel investors.
